中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
News
Careers
Investors
Financials & Filing
2025
2024
2023
2022
2021
2020
2019
2018
2025
2024
2023
2022
2021
2020
2019
2018
Next Day Disclosure Returns - Share Buyback/Others
2025-04-11
Next Day Disclosure Returns - Share Buyback/Others
2025-04-10
Next Day Disclosure Returns - Share Buyback
2025-04-09
Next Day Disclosure Return - Others
2025-04-08
Next Day Disclosure Returns - Share Buyback
2025-04-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
2025-04-07
Next Day Disclosure Returns - Share Buyback/Others
2025-04-03
Replay Link for Obesity Portfolio Webinar on April 2, 2025
2025-04-02
Next Day Disclosure Return - Others
2025-04-01
Inside Information - Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial With ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist
2025-03-31
1
2
3
4
下一页
浙公网安备 33010802003344号
浙ICP备11050387号-1